Kyverna Therapeutics, Inc. (KYTX) Form 8-K — Jul 9, 2026
Kyverna Therapeutics amended its existing $150 million loan facility with Oxford Finance LLC to extend the draw period for the remaining $15 million of Term A loans through December 31, 2026. The amendment requires an upfront cash fee of $187,500 and imposes a 1.0% non-utilization fee on any undrawn Term A funds by the new deadline.
Key figures
- Debt Amount
- 150000000
- Term B range
- 5.0 million to 20.0 million
- Term C total
- 40000000
- Term A remaining
- 15000000
- Term C tranche size
- 20000000
- Term A extension fee
- 187500
- Non utilization fee rate
- 1.0%
Price after filing
1 day: -13.5%7 days: -24.2%30 days: -18.9%
Close on the filing date to close N calendar days later (from $9.81). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.